Expertise in
6
conditions

Simon Ghaly

Sydney, NSW, AU 
Expertise in
6
conditions
Sydney, NSW, AU 

Overview

Simon Ghaly practices practicing medicine in Sydney, Australia.

Mr. Ghaly is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Colitis, Viral Gastroenteritis, Crohn's Disease, Colostomy, and Ileostomy.

He is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Sydney, NSW, Australia
Other Locations
St Vincent's Hospital Sydney
Darlinghurst, NSW, Australia
Eastern Health
Box Hill, VIC 3128, Australia
Nedlands, WA, Australia
Perth, WA, Australia
West Perth, WA, Australia
Murdoch, WA, Australia
Barwon Health
Geelong, VIC, Australia
Level 5, Alma St, Fremanlte, Fremantle, WA 6159, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
View 1 Less Clinical Trial

43 Total Publications

Extended High-Dose Tofacitinib Induction Improves Clinical Response in Ulcerative Colitis: A Multicenter Cohort Study.
Extended High-Dose Tofacitinib Induction Improves Clinical Response in Ulcerative Colitis: A Multicenter Cohort Study.
Journal: JGH open : an open access journal of gastroenterology and hepatology
Published: March 12, 2026

Frequently Asked Questions about Simon Ghaly

Is Simon Ghaly a top-rated expert for Colitis?

MediFind is an objective health platform that identifies experts based on real-world data. Simon Ghaly is classified as an Distinguished expert for Colitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Simon Ghaly participate in research or clinical trials?

Yes. Simon Ghaly has published 43 articles and abstracts on conditions like Colitis. You can view a list of Simon Ghaly's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ghaly's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile